Skip to main
LLY
LLY logo

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 36%
Buy 47%
Hold 8%
Sell 3%
Strong Sell 6%

Bulls say

Eli Lilly has demonstrated substantial growth in its top-line revenue and operational efficiencies, supported by a capable leadership team navigating the company’s strategic initiatives. The company’s robust pipeline, featuring promising developments such as orforglipron, retatrutide, and donanemab, showcases significant potential for further revenue expansion and market penetration, particularly in light of favorable trial results and regulatory support. Revenue projections for 2024, 2025, and 2026 have been positively adjusted to $42.6 billion, $51.0 billion, and $59.7 billion, respectively, indicating sustained growth momentum for the firm.

Bears say

Eli Lilly faces significant revenue risks due to the impending loss of exclusivity for several of its key products, which may lead to increased generic competition and a rapid decline in sales, particularly in the U.S. The company is also vulnerable to heightened pricing pressures and potential setbacks in its drug pipeline, which could further impede growth prospects and negatively impact future revenues and net income. Additionally, unforeseen quality and manufacturing issues could exacerbate these challenges, creating a compounded threat to the firm's financial stability.

Eli Lilly (LLY) has been analyzed by 36 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 47% recommend Buy, 8% suggest Holding, 3% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 36 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $691.03, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $691.03, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.